Haematology 2018

Aims 1. Evaluate the complete remission rate of pembrolizumab combined with ISRT as an alternative to HDT/ASCT in early stage rel/ref HL patients 2. Determine the single agent response rate of pembrolizumab in this population 3. Determine the toxicity and 2-year EFS with this strategy 4. Evaluate biological markers of response and resistance: 1. Tumor and TME immune evasion markers 2. Development of anti-tumor T-cell clonal expansion 3. T-effector:T-reg ratio 4. Serum TARC